Skip to content

Price / book at other companies

Pfizer logo
PfizerPFE
1.8×+0.2×
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
49.5×+44.6×
AbbVie logo
AbbVieABBV
261×+221×
Immunome logo
ImmunomeIMNM
4.2×+2.3×
Arcus Biosciences logo
Arcus BiosciencesRCUS
5.2×+3.6×
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
10.3×+7.2×

Other financials

Income statement

See full
Revenue-
Gross profit-
Operating income-$9.3M-52.6%
Net income-$8.4M-44.6%
EPS (diluted)-$0.05+28.6%

Balance sheet

See full
Cash & equivalents$107.1M+277%
Total debt$871.0K+0.1%
Total equity$107.4M+287%
Total assets$114.2M+227%

Cash flow

See full
Operating cash flow-$8.8M+2.5%

Valuation

See full
Market cap$1.78B+674%
Enterprise value$1.68B+826%

Profitability

See full
Gross margin90%-7.4pp
Operating margin-4,195%-4,591pp
Net margin-4,130.1%-4,444pp
FCF margin-300.5%

Returns & leverage

See full
Return on equity-43.6%-17.9pp
Debt / equity0.0×
Current ratio17.2×+12.6×

Where this comes from

Calculated from SELLAS Life Sciences Group, Inc.’s reported figures.

Based on the most recent quarter.

The official record: SELLAS Life Sciences Group, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about SELLAS Life Sciences Group, Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is SELLAS Life Sciences Group, Inc.'s price / book?
SELLAS Life Sciences Group, Inc. (SLS) reported price / book of 7.1× in Q1 2026.
How has SELLAS Life Sciences Group, Inc.'s price / book changed year-over-year?
SELLAS Life Sciences Group, Inc.'s price / book increased by 100.1% year-over-year, from 3.5× to 7.1×.
What is the long-term trend for SELLAS Life Sciences Group, Inc.'s price / book?
Over 4 years (2020 to 2025), SELLAS Life Sciences Group, Inc.'s price / book has grown at a 23.1% compound annual growth rate (CAGR), from 3.3× to 7.6×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.